Heart Disease And Erectile Dysfunction (Contemporary Cardiology (Totowa, N.J.: Unnumbered).)

It is now generally appreciated that heart disease and its attendant risk factors are a leading cause of erectile dysfunction (ED) and that ED is often an early warning sign of vascular disease. In Heart Disease and Erectile Dysfunction, senior physicians, cardiologists, urologists, psychologists, and pharmacologists critically review the relationship between heart disease and erectile dysfunction and explain for the practicing physician the effective new treatment options available for the cardiac patient with ED. The authors detail in concise language the latest thinking about the risk of sexually induced cardiac events, the efficacy and risks to cardiac patients of drugs used to treat sexual dysfunction, and the expert guidelines developed by prominent organizations on the optimal approach to sexual dysfunction in the cardiac patient. They also discuss the physiology of ED and how the currently available therapies (sildenafil, tadalafil, and vardenafil) may interact with the cardiac system, and the potential application of newer phosphodiesterase-5 inhibitors to cardiovascular disease. Comprehensive and pathbreaking, Heart Disease and Erectile Dysfunction not only clearly delineates for practicing physicians all aspects of the interaction between the vascular system and erectile dysfunction, but also establishes a sound medical basis for the management of cardiac patients suffering erectile disorders.

It is now generally appreciated that erectile dysfunction (ED) is often an early warning sign of vascular disease. Kloner (Good Samaritan Hospital, University of Southern California) collects material by physicians, cardiologists, urologists, psychologists, and pharmacologists, examining the relationship between heart disease and ED and explaining new treatment options for cardiac patients with ED. Contributors review the latest thinking on the risk of sexually induced cardiac events and the risks of drugs used to treat sexual dysfunction, and discuss the physiology of ED and the potential application of newer phosphodiesterase-5 inhibitors to cardiovascular disease. Readership includes cardiologists, urologists, primary care physicians, and sex therapists. Annotation ©2004 Book News, Inc., Portland, OR

Doody Review Services

Reviewer:Allen D. Seftel, MD(Case Western Reserve University)
Description:This well rounded book looks at a new and exciting area of sexual medicine as it relates to the heart and to heart disease. The 18 chapters cover a breadth of sexual medicine and heart disease issues.
Purpose:This book is intended to review the topic of erectile dysfunction from a cardiac standpoint. This is a very important area that is both timely and under-served. The book has exceeded the authors' objectives.
Audience:Although not explicitly stated, this book appears to be written for the practicing clinician. Urologists, cardiologists, and primary care specialists are the main audience for this book. The authors are all highly qualified, well respected authorities in their specific areas.
Features:The topics covered in this book are germane to sexual medicine and cardiovascular disease. There are specific chapters on sildenanfil and its mechanism of action, the importance of phosphodiesterase inhibition to the cardiovascular tree, sexual activity and cardiovascular disease, as well as cardiovascular effects of the phosphodiesterase inhibitors. The book is heavy on text. Additional tables, graphs and figures would be welcome.
Assessment:This is the first book of its kind. Dr Kloner and colleagues deserve credit for bringing this important topic to the forefront.

HEART DISEASE AND ERECTILE DYSFUNCTION......Page 4 PREFACE......Page 6 CONTENTS......Page 7 CONTRIBUTORS......Page 9 1 Physiology of Erection and Causes of Erectile Dysfunction......Page 11 2 Erectile Dysfunction: The Scope of the Problem......Page 29 3 Erectile Dysfunction and Cardiovascular Risk Factors......Page 49 4 Psychologic Aspects of Erectile Dysfunction in Heart Patients......Page 61 5 Management of Erectile Dysfunction: An Overview......Page 75 6 Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway......Page 99 7 Phosphodiesterase-5 Inhibition: Importance to the Cardiovascular System......Page 127 8 The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors......Page 141 9 Cardiovascular Safety of Phosphodiesterase-5 Inhibitors......Page 149 10 Effect of Phosphodiesterase-5 Inhibition on Coronary Blood Flow in Experimental Animals......Page 173 11 Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease......Page 189 12 Cardiovascular Effects of Nonphosphodiesterase-5 Inhibitor Erectile Dysfunction Therapies......Page 205 13 Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition......Page 217 14 The Physiologic Cost of Sexual Activity......Page 249 15 Sexual Activity As a Trigger of Myocardial Infarction/Ischemia: Implications for Treating Erectile Dysfunction......Page 261 16 Sex After Cardiac Events and Procedures: Counseling From the Cardiovascular Specialist’s Perspective......Page 271 17 American College of Cardiology/American Heart Association Guidelines on the Use of Sildenafil in Patients With Cardiovascular Disease......Page 281 18 Risk of Heart Attack After Sexual Activity: The Princeton Guidelines and Their Rationale......Page 289 INDEX......Page 299 Senior physicians, cardiologists, urologists, psychologists, and pharmacologists critically review the relation between heart disease and erectile dysfunction (ED) and explain for the practicing physician the effective new treatment options available for the cardiac patient with ED. The authors detail in concise language the latest thinking about the risk of sexually induced cardiac events, the efficacy and risks to cardiac patients of drugs used to treat sexual dysfunction, and the expert guidelines developed by prominent organizations on the optimal approach to sexual dysfunction in the cardiac patient. They also discuss the physiology of ED and the currently available therapies (sildenafil, tadalafil, and vardenafil) may interact with the cardiac system, and the potential application of newer agents like phosphodiesterase-5 inhibitors to cardiovascular disease. In This Book, Senior Physicians, Cardiologists, Urologists, Psychologists, And Pharmacologists Critically Review The Relationship Between Heart Disease And Erectile Dysfunction And Explain For The Practicing Physician The Effective New Treatment Options Available For The Cardiac Patient With Ed. Edited By Robert A. Kloner. Includes Bibliographical References And Index. Univ. of Southern California, Los Angeles. Focuses on the common connection between cardiovascular disease and erectile dysfunction. Addresses new treatment options, including risks and side effects. Also analyzes the dangers of sexual activity in cardiac patients. For physicians. DNLM: Impotence--etiology. Erectile dysfunction (ED), defined as "the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance" (1), is a highly prevalent condition.